查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1636791

2030 年丙型肝炎藥物市場預測：按產品、治療類型、藥物類別、給藥途徑、疾病階段、最終用戶和地區進行的全球分析

Hepatitis C Drugs Market Forecasts to 2030 - Global Analysis By Product (Generic Hepatitis C Drugs and Branded Hepatitis C Drugs), Treatment Type, Drug Class, Route Of Administration, Disease Stage, End User and By Geography
出版日期: | 出版商: Stratistics Market Research Consulting | 英文 200+ Pages | 商品交期: 2-3個工作天內

價格

根據 Stratistics MRC 的數據，全球丙型肝炎藥物市場預計在 2024 年達到 259.2 億美元，到 2030 年將達到 365.7 億美元，預測期內的複合年成長率為 6.2%。

丙型肝炎藥物是用於治療C型肝炎（一種影響肝臟的病毒感染疾病）的藥物。這些藥物透過在C型肝炎病毒(HCV) 生命週期的不同階段發揮作用，要么阻止病毒複製，要么增強免疫系統抵抗病毒的能力。這些藥物通常合併使用，以顯著提高治癒率，縮短治療時間，並最大限度地減少副作用。

根據美國疾病管制與預防美國（CDC）2016年的數據，美國約有350萬人患有慢性C型肝炎。

丙型肝炎盛行率不斷上升

隨著越來越多的人被診斷出患有丙型肝炎，對先進治療方案的需求也日益成長，尤其是直接抗病毒藥物 (DAA)，這些藥物以高效和副作用小而聞名。公共衛生措施和宣傳宣傳活動進一步加強了篩檢和早期檢測工作，從而增加了尋求治療的患者數量。此外，醫療保健提供者和政府致力於消除丙型肝炎，對研究、津貼和夥伴關係關係的投資有助於擴大市場並改善獲得丙型肝炎藥物的機會。

副作用和抗藥性

丙型肝炎藥物的副作用和抗藥性是由患者反應的多變性和病毒的變異能力所造成的。一些治療方法，尤其是像干擾素治療方法這樣的老療法，會引起嚴重的副作用，如疲勞、憂鬱和類流感症狀，從而降低患者的依從性。這些因素限制了治療的有效性，增加了對替代療法的需求，降低了患者信心，並最終減緩了採用和治療完成率，從而阻礙了市場成長。

擴大醫療基礎設施和保險覆蓋範圍

衛生基礎設施的改善將提高人們獲得診斷和治療設施的機會，從而能夠早期發現丙型肝炎並及時干預。擴大保險覆蓋範圍將減輕患者的經濟負擔，使得 DAA 等昂貴的治療更加實惠。政府措施和私營部門對醫療保健系統的投資（尤其是在新興經濟體中）確保了先進治療的可用性，從而進一步推動了市場成長。這些發展將使更多患者能夠接受治療，增加對有效丙型肝炎藥物的需求並改善整體健康。

學名藥的競爭

學名藥以極低的成本提供類似的功效，吸引了注重價格的患者和醫療保健提供者。這種轉變限制了高價品牌藥的市場佔有率，尤其是在中低收入地區。而學名藥的推出往往引發價格戰，進一步擠壓主要企業的利潤空間。具有成本效益的學名藥的供應也可能阻礙對開發新藥的投資，從而減緩丙型肝炎治療的創新。

COVID-19 的影響

COVID-19 疫情對C型肝炎藥物市場產生了重大影響，擾亂了醫療保健系統、診斷和治療。由於醫療資源被轉移到控制 COVID-19，丙型肝炎的診斷和治療被推遲。此外，旅行限制和封鎖影響了患者獲得治療和藥物的機會。但公眾健康意識和遠端醫療的增強有助於維持一些治療工作。此次疫情也將重點轉移到加強衛生基礎設施上，這可能有助於未來疫情後的丙型肝炎管理。

預測期內單一療法市場規模預計最大

預計單一療法領域將在整個預測期內佔據最大的市場佔有率。丙型肝炎單一療法治療是指使用單一抗病毒藥物治療感染疾病。單一療法包括干擾素和Ribavirin，但隨著直接抗病毒藥物（DAA）的出現，單一療法變得更有效且耐受性更好。它們通常用於具有特定基因型或症狀較輕的患者，以確保療效同時最大限度地減少副作用。

預測期內，慢性丙型肝炎市場預計將以最高複合年成長率成長

預計預測期內慢性丙型肝炎部分將出現最高的複合年成長率。用於治療慢性C型肝炎的C型肝炎藥物主要用於消除體內的病毒和預防肝損傷。這些藥物通常合併使用，具有很高的療效和治癒率，且副作用小。治療通常持續8至12週，這些治療方法有助於減少肝硬化、肝癌和肝功能衰竭等併發症。

比最大的地區

由於人們認知的提高、醫療保健機會的改善以及丙型肝炎患病率的上升，預計亞太地區將在預測期內佔據最大的市場佔有率。印度、中國和日本等國家因患者人數眾多且政府醫療保健措施而主導市場。該地區也是百時美施貴寶、西普拉和雷迪博士實驗室等主要企業的所在地。快速的都市化、不斷擴大的醫療保健基礎設施以及有利的政府政策正在推動該地區的市場成長。

複合年成長率最高的地區：

由於北美擁有先進的醫療保健體系和對研發的大量投資，預計在預測期內北美將實現最高的複合年成長率。該地區的主要企業包括吉利德科學、艾伯維、默克公司和百時美施貴寶。由於政府資助的醫療保健計劃、保險覆蓋範圍的擴大以及丙型肝炎消除努力的加強，該地區的市場正在穩步成長。 DAA 的採用和針對高風險族群的努力改善了治療的機會和結果，確保北美仍然是全球主導市場。

免費客製化服務

訂閱此報告的客戶可享有以下免費自訂選項之一：

  • 公司簡介
    • 全面分析其他市場參與者（最多 3 家公司）
    • 主要企業的 SWOT 分析（最多 3 家公司）
  • 地理細分
    • 根據客戶興趣對主要國家進行的市場估計、預測和複合年成長率（註：基於可行性檢查）
  • 競爭性基準化分析
    • 根據產品系列、地理分佈和策略聯盟對主要企業進行基準化分析

目錄

第1章執行摘要

第 2 章 前言

  • 概述
  • 相關利益者
  • 研究範圍
  • 調查方法
    • 資料探勘
    • 資料分析
    • 資料檢驗
    • 研究途徑
  • 研究資訊來源
    • 主要研究資訊來源
    • 二手研究資料資訊來源
    • 先決條件

第3章 市場走勢分析

  • 驅動程式
  • 限制因素
  • 機會
  • 威脅
  • 產品分析
  • 最終用戶分析
  • 新興市場
  • COVID-19 的影響

第 4 章 波特五力分析

  • 供應商的議價能力
  • 買家的議價能力
  • 替代品的威脅
  • 新進入者的威脅
  • 競爭對手之間的競爭

第 5 章 全球丙型肝炎藥物市場（按產品）

  • 非專利肝炎藥物
  • 品牌丙型肝炎藥物

6. 全球丙型肝炎藥物市場依治療類型分類

  • 聯合治療
  • 單藥治療

7. 全球丙型肝炎藥物市場（依藥物類別）

  • 直接抗病毒藥物 (DAA)
  • 蛋白酶抑制劑
  • NS5A 抑制劑
  • NS5B 抑制劑
  • 伴隨用藥
  • Ribavirin
  • 其他藥物類別

8. 全球丙型肝炎藥物市場依給藥途徑分類

  • 口服藥物
  • 注射藥物

第 9 章 全球C型肝炎藥物市場（依疾病階段）

  • 急性C型肝炎
  • 慢性C型肝炎

第 10 章 全球C型肝炎藥物市場（依最終使用者）

  • 醫院
  • 診所
  • 研究和診斷實驗室
  • 其他最終用戶

第 11 章 全球丙型肝炎藥物市場（按地區）

  • 北美洲
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 德國
    • 英國
    • 義大利
    • 法國
    • 西班牙
    • 其他歐洲國家
  • 亞太地區
    • 日本
    • 中國
    • 印度
    • 澳洲
    • 紐西蘭
    • 韓國
    • 其他亞太地區
  • 南美洲
    • 阿根廷
    • 巴西
    • 智利
    • 南美洲其他地區
  • 中東和非洲
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 卡達
    • 南非
    • 其他中東和非洲地區

第12章 重大進展

  • 協議、夥伴關係、合作和合資企業
  • 收購與合併
  • 新產品發布
  • 業務擴展
  • 其他關鍵策略

第13章 公司概況

  • Gilead Sciences
  • AbbVie
  • Merck & Co.
  • Johnson & Johnson
  • Bristol-Myers Squibb
  • Roche
  • GlaxoSmithKline
  • Eli Lilly and Company
  • Novartis
  • Sanofi
  • Pfizer
  • Boehringer Ingelheim
  • Mylan Pharmaceuticals
  • Teva Pharmaceuticals
  • Cipla
  • Hetero Drugs
  • NephroPlus
  • Aurobindo Pharma
  • Dr. Reddy's Laboratories
  • Zydus Cadila
Product Code: SMRC28433

According to Stratistics MRC, the Global Hepatitis C Drugs Market is accounted for $25.92 billion in 2024 and is expected to reach $36.57 billion by 2030 growing at a CAGR of 6.2% during the forecast period. Hepatitis C drugs are medications used to treat Hepatitis C, a viral infection that affects the liver. These drugs work by targeting the Hepatitis C virus (HCV) at various stages of its lifecycle, such as preventing viral replication or boosting the immune system's ability to fight the virus. These drugs are often used in combination, have significantly improved cure rates, reduced treatment durations, and minimized side effects.

According to the Centers for Disease Control and Prevention (CDC) in 2016, an estimated 3.5 million people in the United States suffered from chronic hepatitis C.

Market Dynamics:

Driver:

Increasing prevalence of hepatitis C

As more people are diagnosed with the infection, there is a growing need for advanced treatment options, particularly Direct-Acting Antivirals (DAAs), known for their high efficacy and minimal side effects. Public health initiatives and awareness campaigns further amplify screening and early detection efforts, creating a larger patient pool seeking treatment. Additionally, healthcare providers and governments focus on eradicating the disease, leading to investments in research, subsidies, and partnerships, which support market expansion and improved accessibility to Hepatitis C drugs.

Restraint:

Side effects and drug resistance

Side effects and drug resistance in Hepatitis C drugs stem from the variability in patient response and the virus's ability to mutate. Some treatments, particularly older regimens like interferon-based therapies, cause significant side effects, such as fatigue, depression, and flu-like symptoms, discouraging patient adherence. These factors hamper market growth by limiting treatment efficacy, increasing the need for alternative therapies, and reducing patient trust, ultimately slowing adoption and treatment completion rates.

Opportunity:

Expanding healthcare infrastructure and insurance coverage

Improved healthcare infrastructure increases access to diagnostic and treatment facilities, enabling earlier detection and timely intervention for Hepatitis C. Enhanced insurance coverage lowers the financial burden on patients, making expensive therapies like DAAs more affordable. Government initiatives and private sector investments in healthcare systems, particularly in emerging economies, further drive market growth by ensuring the availability of advanced treatments. These developments collectively encourage more patients to seek care, boosting demand for effective Hepatitis C drugs and improving overall health outcomes.

Threat:

Competition from generic drugs

Generics offer similar efficacy at a fraction of the cost, attracting price-sensitive patients and healthcare providers. This shift limits the market share of premium-priced branded drugs, especially in low- and middle-income regions. Additionally, the introduction of generics often leads to price wars, further compressing profit margins for companies. The availability of cost-effective generics also discourages investment in new drug development, potentially slowing innovation in the Hepatitis C treatment landscape.

Covid-19 Impact

The covid-19 pandemic significantly impacted the hepatitis C drugs market, disrupting healthcare systems, diagnostics, and treatments. The diversion of healthcare resources to manage covid led to delays in hepatitis C diagnosis and treatment initiation. Additionally, travel restrictions and lockdowns affected patient access to care and medications. However, increased awareness of public health and telemedicine helped sustain some treatment efforts. The pandemic also shifted focus toward enhancing healthcare infrastructure, which may aid in future Hepatitis C management post-covid.

The monotherapy segment is expected to be the largest during the forecast period

The monotherapy segment is predicted to secure the largest market share throughout the forecast period. Monotherapy in Hepatitis C treatment refers to using a single antiviral drug to treat the infection. Monotherapy involves interferon or ribavirin, but with the advent of Direct-Acting Antivirals (DAAs), monotherapy has become more effective and well-tolerated. It is often used for patients with specific genotypes or mild disease, minimizing side effects while ensuring effectiveness.

The chronic hepatitis C segment is expected to have the highest CAGR during the forecast period

The chronic hepatitis C segment is anticipated to witness the highest CAGR during the forecast period. Hepatitis C drugs used in chronic Hepatitis C treatment are primarily focused on eliminating the virus from the body and preventing liver damage. These drugs, often used in combination, are highly effective, offering high cure rates with minimal side effects. Treatment duration typically ranges from 8 to 12 weeks, and these therapies help reduce complications like cirrhosis, liver cancer, and liver failure.

Region with largest share:

Asia Pacific is expected to register the largest market share during the forecast period due to increasing awareness, improved healthcare access, and rising Hepatitis C prevalence. Countries like India, China, and Japan dominate the market, driven by large patient populations and government health initiatives. The region is also home for key players such as Bristol-Myers Squibb, Cipla, and Dr. Reddy's Laboratories. Rapid urbanization, expanding healthcare infrastructure, and favorable government policies are propelling the market's growth in this region.

Region with highest CAGR:

North America is expected to witness the highest CAGR over the forecast period driven by advanced healthcare systems and substantial investments in research and development. Key players in the region include Gilead Sciences, AbbVie Inc., Merck & Co., and Bristol-Myers Squibb. The region experiences steady market growth due to government-supported health programs, insurance coverage, and increasing efforts to eradicate Hepatitis C. The adoption of DAAs, coupled with initiatives targeting high-risk populations, ensures improved treatment access and outcomes, solidifying North America as a dominant market globally.

Key players in the market

Some of the key players profiled in the Hepatitis C Drugs Market include Gilead Sciences, AbbVie, Merck & Co., Johnson & Johnson, Bristol-Myers Squibb, Roche, GlaxoSmithKline, Eli Lilly and Company, Novartis, Sanofi, Pfizer, Boehringer Ingelheim, Mylan Pharmaceuticals, Teva Pharmaceuticals, Cipla, Hetero Drugs, NephroPlus, Aurobindo Pharma, Dr. Reddy's Laboratories and Zydus Cadila.

Key Developments:

In September 2024, NephroPlus has introduced a pioneering program aimed at addressing the critical issue of Hepatitis C in haemodialysis patients, particularly in regions with limited healthcare resources. This initiative highlights NephroPlus' ongoing commitment to enhancing patient care and reinforcing the health system's capabilities.

In April 2022, Bristol-Myers Squibb & Gilead Sciences entered a strategic collaboration to further develop their Hepatitis C drug pipelines. The deal focused on the combined development of new combination therapies for chronic Hepatitis C virus (HCV) infections, leveraging both companies' research assets to expand treatment options and improve cure rates.

Products Covered:

  • Generic Hepatitis C Drugs
  • Branded Hepatitis C Drugs

Treatment Types Covered:

  • Combination Therapy
  • Monotherapy

Drug Classes Covered:

  • Direct-Acting Antivirals (DAAs)
  • Protease Inhibitors
  • NS5A Inhibitors
  • NS5B Inhibitors
  • Combination Drugs
  • Ribavirin
  • Other Drug Classes

Route Of Administrations Covered:

  • Oral Drugs
  • Injectable Drugs

Disease Stages Covered:

  • Acute Hepatitis C
  • Chronic Hepatitis C

End Users Covered:

  • Hospitals
  • Clinics
  • Research & Diagnostic Laboratories
  • Other End Users

Regions Covered:

  • North America
    • US
    • Canada
    • Mexico
  • Europe
    • Germany
    • UK
    • Italy
    • France
    • Spain
    • Rest of Europe
  • Asia Pacific
    • Japan
    • China
    • India
    • Australia
    • New Zealand
    • South Korea
    • Rest of Asia Pacific
  • South America
    • Argentina
    • Brazil
    • Chile
    • Rest of South America
  • Middle East & Africa
    • Saudi Arabia
    • UAE
    • Qatar
    • South Africa
    • Rest of Middle East & Africa

What our report offers:

  • Market share assessments for the regional and country-level segments
  • Strategic recommendations for the new entrants
  • Covers Market data for the years 2022, 2023, 2024, 2026, and 2030
  • Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
  • Strategic recommendations in key business segments based on the market estimations
  • Competitive landscaping mapping the key common trends
  • Company profiling with detailed strategies, financials, and recent developments
  • Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

  • Company Profiling
    • Comprehensive profiling of additional market players (up to 3)
    • SWOT Analysis of key players (up to 3)
  • Regional Segmentation
    • Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
  • Competitive Benchmarking
    • Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

Table of Contents

1 Executive Summary

2 Preface

  • 2.1 Abstract
  • 2.2 Stake Holders
  • 2.3 Research Scope
  • 2.4 Research Methodology
    • 2.4.1 Data Mining
    • 2.4.2 Data Analysis
    • 2.4.3 Data Validation
    • 2.4.4 Research Approach
  • 2.5 Research Sources
    • 2.5.1 Primary Research Sources
    • 2.5.2 Secondary Research Sources
    • 2.5.3 Assumptions

3 Market Trend Analysis

  • 3.1 Introduction
  • 3.2 Drivers
  • 3.3 Restraints
  • 3.4 Opportunities
  • 3.5 Threats
  • 3.6 Product Analysis
  • 3.7 End User Analysis
  • 3.8 Emerging Markets
  • 3.9 Impact of Covid-19

4 Porters Five Force Analysis

  • 4.1 Bargaining power of suppliers
  • 4.2 Bargaining power of buyers
  • 4.3 Threat of substitutes
  • 4.4 Threat of new entrants
  • 4.5 Competitive rivalry

5 Global Hepatitis C Drugs Market, By Product

  • 5.1 Introduction
  • 5.2 Generic Hepatitis C Drugs
  • 5.3 Branded Hepatitis C Drugs

6 Global Hepatitis C Drugs Market, By Treatment Type

  • 6.1 Introduction
  • 6.2 Combination Therapy
  • 6.3 Monotherapy

7 Global Hepatitis C Drugs Market, By Drug Class

  • 7.1 Introduction
  • 7.2 Direct-Acting Antivirals (DAAs)
  • 7.3 Protease Inhibitors
  • 7.4 NS5A Inhibitors
  • 7.5 NS5B Inhibitors
  • 7.6 Combination Drugs
  • 7.7 Ribavirin
  • 7.8 Other Drug Classes

8 Global Hepatitis C Drugs Market, By Route Of Administration

  • 8.1 Introduction
  • 8.2 Oral Drugs
  • 8.3 Injectable Drugs

9 Global Hepatitis C Drugs Market, By Disease Stage

  • 9.1 Introduction
  • 9.2 Acute Hepatitis C
  • 9.3 Chronic Hepatitis C

10 Global Hepatitis C Drugs Market, By End User

  • 10.1 Introduction
  • 10.2 Hospitals
  • 10.3 Clinics
  • 10.4 Research & Diagnostic Laboratories
  • 10.5 Other End Users

11 Global Hepatitis C Drugs Market, By Geography

  • 11.1 Introduction
  • 11.2 North America
    • 11.2.1 US
    • 11.2.2 Canada
    • 11.2.3 Mexico
  • 11.3 Europe
    • 11.3.1 Germany
    • 11.3.2 UK
    • 11.3.3 Italy
    • 11.3.4 France
    • 11.3.5 Spain
    • 11.3.6 Rest of Europe
  • 11.4 Asia Pacific
    • 11.4.1 Japan
    • 11.4.2 China
    • 11.4.3 India
    • 11.4.4 Australia
    • 11.4.5 New Zealand
    • 11.4.6 South Korea
    • 11.4.7 Rest of Asia Pacific
  • 11.5 South America
    • 11.5.1 Argentina
    • 11.5.2 Brazil
    • 11.5.3 Chile
    • 11.5.4 Rest of South America
  • 11.6 Middle East & Africa
    • 11.6.1 Saudi Arabia
    • 11.6.2 UAE
    • 11.6.3 Qatar
    • 11.6.4 South Africa
    • 11.6.5 Rest of Middle East & Africa

12 Key Developments

  • 12.1 Agreements, Partnerships, Collaborations and Joint Ventures
  • 12.2 Acquisitions & Mergers
  • 12.3 New Product Launch
  • 12.4 Expansions
  • 12.5 Other Key Strategies

13 Company Profiling

  • 13.1 Gilead Sciences
  • 13.2 AbbVie
  • 13.3 Merck & Co.
  • 13.4 Johnson & Johnson
  • 13.5 Bristol-Myers Squibb
  • 13.6 Roche
  • 13.7 GlaxoSmithKline
  • 13.8 Eli Lilly and Company
  • 13.9 Novartis
  • 13.10 Sanofi
  • 13.11 Pfizer
  • 13.12 Boehringer Ingelheim
  • 13.13 Mylan Pharmaceuticals
  • 13.14 Teva Pharmaceuticals
  • 13.15 Cipla
  • 13.16 Hetero Drugs
  • 13.17 NephroPlus
  • 13.18 Aurobindo Pharma
  • 13.19 Dr. Reddy's Laboratories
  • 13.20 Zydus Cadila

List of Tables

  • Table 1 Global Hepatitis C Drugs Market Outlook, By Region (2022-2030) ($MN)
  • Table 2 Global Hepatitis C Drugs Market Outlook, By Product (2022-2030) ($MN)
  • Table 3 Global Hepatitis C Drugs Market Outlook, By Generic Hepatitis C Drugs (2022-2030) ($MN)
  • Table 4 Global Hepatitis C Drugs Market Outlook, By Branded Hepatitis C Drugs (2022-2030) ($MN)
  • Table 5 Global Hepatitis C Drugs Market Outlook, By Treatment Type (2022-2030) ($MN)
  • Table 6 Global Hepatitis C Drugs Market Outlook, By Combination Therapy (2022-2030) ($MN)
  • Table 7 Global Hepatitis C Drugs Market Outlook, By Monotherapy (2022-2030) ($MN)
  • Table 8 Global Hepatitis C Drugs Market Outlook, By Drug Class (2022-2030) ($MN)
  • Table 9 Global Hepatitis C Drugs Market Outlook, By Direct-Acting Antivirals (DAAs) (2022-2030) ($MN)
  • Table 10 Global Hepatitis C Drugs Market Outlook, By Protease Inhibitors (2022-2030) ($MN)
  • Table 11 Global Hepatitis C Drugs Market Outlook, By NS5A Inhibitors (2022-2030) ($MN)
  • Table 12 Global Hepatitis C Drugs Market Outlook, By NS5B Inhibitors (2022-2030) ($MN)
  • Table 13 Global Hepatitis C Drugs Market Outlook, By Combination Drugs (2022-2030) ($MN)
  • Table 14 Global Hepatitis C Drugs Market Outlook, By Ribavirin (2022-2030) ($MN)
  • Table 15 Global Hepatitis C Drugs Market Outlook, By Other Drug Classes (2022-2030) ($MN)
  • Table 16 Global Hepatitis C Drugs Market Outlook, By Route Of Administration (2022-2030) ($MN)
  • Table 17 Global Hepatitis C Drugs Market Outlook, By Oral Drugs (2022-2030) ($MN)
  • Table 18 Global Hepatitis C Drugs Market Outlook, By Injectable Drugs (2022-2030) ($MN)
  • Table 19 Global Hepatitis C Drugs Market Outlook, By Disease Stage (2022-2030) ($MN)
  • Table 20 Global Hepatitis C Drugs Market Outlook, By Acute Hepatitis C (2022-2030) ($MN)
  • Table 21 Global Hepatitis C Drugs Market Outlook, By Chronic Hepatitis C (2022-2030) ($MN)
  • Table 22 Global Hepatitis C Drugs Market Outlook, By End User (2022-2030) ($MN)
  • Table 23 Global Hepatitis C Drugs Market Outlook, By Hospitals (2022-2030) ($MN)
  • Table 24 Global Hepatitis C Drugs Market Outlook, By Clinics (2022-2030) ($MN)
  • Table 25 Global Hepatitis C Drugs Market Outlook, By Research & Diagnostic Laboratories (2022-2030) ($MN)
  • Table 26 Global Hepatitis C Drugs Market Outlook, By Other End Users (2022-2030) ($MN)

Note: Tables for North America, Europe, APAC, South America, and Middle East & Africa Regions are also represented in the same manner as above.